Compugen Ltd. (CGEN)
NASDAQ: CGEN · Real-Time Price · USD
1.830
+0.020 (1.10%)
Feb 3, 2026, 12:05 PM EST - Market open
Compugen Market Cap
Compugen has a market cap or net worth of $171.17 million as of February 3, 2026. Its market cap has decreased by -9.82% in one year.
Market Cap
171.17M
Enterprise Value
87.09M
1-Year Change
-9.82%
Ranking
Category
Stock Price
$1.83
Market Cap Chart
Since December 31, 2002, Compugen's market cap has increased from $46.50M to $171.17M, an increase of 268.11%. That is a compound annual growth rate of 5.80%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 2, 2026 | 169.30M | 18.31% |
| Dec 31, 2025 | 143.10M | 4.45% |
| Dec 31, 2024 | 137.00M | -21.58% |
| Dec 29, 2023 | 174.70M | 181.77% |
| Dec 30, 2022 | 62.00M | -82.82% |
| Dec 31, 2021 | 360.80M | -64.38% |
| Dec 31, 2020 | 1.01B | 183.96% |
| Dec 31, 2019 | 356.70M | 220.49% |
| Dec 31, 2018 | 111.30M | -12.91% |
| Dec 29, 2017 | 127.80M | -50.45% |
| Dec 30, 2016 | 257.90M | -19.68% |
| Dec 31, 2015 | 321.10M | -5.97% |
| Dec 31, 2014 | 341.50M | 4.27% |
| Dec 31, 2013 | 327.50M | 91.74% |
| Dec 31, 2012 | 170.80M | 1.73% |
| Dec 30, 2011 | 167.90M | 3.83% |
| Dec 31, 2010 | 161.70M | 16.92% |
| Dec 31, 2009 | 138.30M | 1,033.61% |
| Dec 31, 2008 | 12.20M | -72.95% |
| Dec 31, 2007 | 45.10M | -37.45% |
| Dec 29, 2006 | 72.10M | -38.95% |
| Dec 30, 2005 | 118.10M | -14.61% |
| Dec 31, 2004 | 138.30M | 4.38% |
| Dec 31, 2003 | 132.50M | 184.95% |
| Dec 31, 2002 | 46.50M | - |
View and export this data all the way back to 2002. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| NeOnc Technologies Holdings | 180.53M |
| Sol-Gel Technologies | 179.70M |
| Cartesian Therapeutics | 176.56M |
| Innate Pharma | 171.43M |
| Kalaris Therapeutics | 170.38M |
| Molecular Partners AG | 170.21M |
| Prelude Therapeutics | 167.27M |
| ProQR Therapeutics | 163.29M |